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Abstract
Background: Ischemic preconditioning (IPC) and postconditioning (POC) are well docu-
mented to trigger cardioprotection against ischemia/reperfusion (I/R) injury, but the effect of 
their both co-application remains unclear in human heart. The present study sought to assess 
the co-application of IPC and POC on fragments of human myocardium in vitro. 
Methods: Muscular trabeculae of the human right atrial were electrically driven in the organ 
bath and subjected to simulated I/R injury – hypoxia/re-oxygenation injury in vitro. To achie-
ve IPC of trabeculae the single brief hypoxia period preceded the applied lethal hypoxia, and 
to achieve POC triple brief hypoxia periods followed the lethal hypoxia. Additional muscular 
trabeculae were exposed only to the hypoxic stimulation (Control) or were subjected to the non-
-hypoxic stimulation (Sham). 10 µM norepinephrine (NE) application ended every experiment 
to assess viability of trabeculae. The contraction force of the myocardium assessed as a ma-
ximal amplitude of systolic peak (%Amax) was obtained during the whole experiment’s period. 
Results: Co-application of IPC and POC resulted in decrease in %Amax during the re-oxy- 
gentaion period and after NE application, as compared to Control (30.35 ± 2.25 vs. 41.89 ± 2.25,  
56.26 ± 7.73 vs. 65.98 ± 5.39, respectively). This was in contrary to the effects observed when 
IPC and POC were applied separately.
Conclusions: The co-application of IPC and POC abolishes the cardioprotection of either 
intervention alone against simulated I/R injury in fragments of the human right heart atria.  
(Cardiol J 2013; 20, 5: 472–477)
Key words: ischemia, reperfusion, preconditioning, postconditioning 
Introduction
The restoration of coronary flow is necessary 
to reduce ischemic myocardial damage due to acute 
vessel occlusion. However, during the reperfusion 
period, an additional damage of cardiac tissue 
occurs resulting in an ischemia/reperfusion (I/R) 
injury [1]. I/R injury causes a necrosis and apopto-
sis of cardiomyocytes and in clinical settings it may 
manifests as a myocardial stunning observed after 
the global ischemia during the cardiac surgery [2] 
or as an impaired coronary flow (no-flow pheno - 
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menon) [3] due to microvessels dysfunction observed 
after the percutaneous coronary angioplasty. 
Sequences of brief ischemia periods applied 
before (preconditioning — IPC) or after (postcondi-
tioning — POC) the prolonged coronary occlusion 
was documented to protect the human heart against 
I/R injury in in vitro [4, 5] and in in vivo studies 
[6–10]. Since IPC and POC act at the opposite 
stages of ischemia, thus the question arise if their 
protective capacity is similar and if their co-appli-
cation can ensure better overall cardioprotection 
against I/R injury in human heart.
We aimed to assess the influence of IPC and 
POC co-application on the simulated I/R injury 
outcomes in the human myocardium. Hence in the 
following study, we have tested several protocols 
of IPC to identify the one producing the maximal 
protection. Such selected IPC protocol was than 
combined with the POC protocol that proved to be 
cardioprotective in previous studies [9, 10]. 
Methods
The experiments were performed on muscu-
lar trabeculae obtained from the right heart atrial 
appendages of 44 consecutive patients (32 males/ 
/12 females) subjected to the coronary artery bypass 
surgery. Patients with diagnosed diabetes, a signi-
ficant valvular heart disease and subjected to oral 
statin therapy were excluded from the study.
The fragments of the human right heart atria 
were transported from the cardiac surgery room 
to the laboratory in an ice-cold Krebs-Henseleit 
solution ([M]: NaCl 118.0, KCl 4.70, CaCl2 1.52, 
MgSO4 1.64, NaHCO3 24.88, KH2PO4 1.18, glu-
cose 11.0, and sodium pyruvate 2.0; pH 7.4). Two 
muscular trabeculae, each less than 1 mm in dia-
meter, were dissected from the 1 fragment of the 
right heart atria and incubated in 2 separate organ 
baths (Schuler Organbath, Hugo Sachs Elektronik, 
March-Hugstetten, Germany [HSE]) both filled 
with Krebs-Henseleit solution warmed up to 37oC. 
Two trabeculae from 1 patient were always studied 
simultaneously using POC or IPC protocol and only 
hypoxia protocol (Control). Additional trabeculae 
were exposed to 120-min non-hypoxic stimulation 
in the sham protocol (Sham). All trabeculae, except 
those in Sham protocol, were exposed to hypoxia 
protocol including: 60 min of hypoxia (the trabe-
cula was incubated in the Krebs-Henseleit buffer 
deprivated of glucose and pyruvate and saturated 
with 95% argon and 5% carbon dioxide) with subse-
quent 60 min of re-oxygenation (the trabecula was 
incubated in the stanadard Krebs-Henseleit buffer 
saturated with the 95% oxygen and 5% carbon 
dioxide). The buffer was replaced every 15 min, 
except the time of hypoxia. Every trabecula was 
stretched to 90% of its optimal tension strength, 
according to the Frank-Starling relationship and all 
trabeculae were driven throughout experiments 
with 1 Hz 50 ms square stimuli using platinum 
field electrodes and a stimulator (Type 215, HSE) 
as described previously [11]. The systolic function 
of the every trabecula was recorded with the use an 
F30 isometric force transducer (Type 372, HSE). 
The signal was enhanced with a bridge amplifier 
(Type 336, HSE) and recorded by a PowerLab/4SP 
system and analyzed off-line using Chart software 
(AD Instruments, Chalgrove, Oxfordshire, UK).
POC protocol consisted of 3 times repeated 
sequence of 1-min re-oxygenation with subse-
quent 1-min hypoxia applied at the beginning of 
60 min re-oxygenation during hypoxia protocol. 
The number of the ischemic cycles was based on 
previously published data [9, 10]. Three experi-
ments of IPC protocol were performed to identify 
the 1 producing maximal cadioprotection. The 
1st IPC protocol consisted of 5-min hypoxia with 
subsequent 5-min of re-oxygenation applied be-
fore hypoxia protocol (IPC-1), the 2nd consisted of 
2 periods of 5-min hypoxia with subsequent 5-min 
of re-oxygenation applied before hypoxia protocol 
(IPC-2) and 3rd consisted of 3 periods of 5-min 
hypoxia with subsequent 5-min of re-oxygenation 
applied before hypoxia protocol (IPC-3). The last 
experimental protocol consisted of combined IPC 
and POC protocols (IPC-2 + POC) applied in one 
trabecula simultaneously. 
Each experimental protocol was completed 
with 10 µM of the norepinephrine (NE) application. 
The level of the time depending on decline of the 
myocardial systolic function in our bio-assay set-
ting was the net effect of necrosis and/or apoptosis 
in incubated myocardial strip which leads to the 
loss of its viability. The percentage recovery of the 
myocardial function obtained after NE application 
was the measure of (1) tissue viability at the end 
of protocol and (2) the achieved by protocol car-
dioprotection [12].
The systolic function was assessed by the me-
asurement of the maximal amplitude of the systolic 
peak (Amax [mV]). Amax was obtained in 10th, 15th, 30th, 
45th and 60th min of re-oxygenation and after the NE 
application. The Amax values were presented as the 
percent of Amax obtained before any experimental 
protocol application (%Amax).
The Local Bioethics Committee approval for 
the use of human tissue was obtained and individual 
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patient consent was waived. All experiments were 
performed according to the principles stated in the 
Declaration of Helsinki.
Statistical analysis
All continuous data were normally distributed 
and were presented as a mean ± standard error of 
the mean (SEM). Chi-square analysis were used to 
compare categorical data of patients’ characteristic. 
Two-way ANOVA was used to compare the results 
of %Amax values from 10th to 60th min of re-oxyge-
nation. Paired Student’s t-test was performed to 
compare patients’ age and %Amax values obtained in 
the 60th min re-oxygenation or after NE application. 
A substraction sum of %Amax values between 
IPC-1, IPC-2, POC and corresponding control 
were evaluated to assess differences in the myo-
cardial response to used experimental protocols 
(dif-IPC-1, dif-IPC-2 and dif-POC respectively). 
dif-IPC-1, dif-IPC-2 and dif-POC results were 
compared by 2-way ANOVA for values obtained 
together between 10th to 60th min of re-oxygenation 
and by unpaired Student t-test for values obtained 
in the 60th min of re-oxygenation or after NE appli-
cation (SigmaPlot 10.0.1.2., Systat Software Inc.).
Results
Patients’ characteristics
There were no significant differences in age, 
sex and pharmacotherapy between patients subje-
cted to Sham, IPC-1, IPC-2, IPC-3 POC and IPC 
+ POC protocols (Table 1).
Preconditioning 
Maximal amplitude of systolic peak values 
were significantly higher for IPC-1 and IPC-2 
protocols vs. Control from 10th to 60th min of re-
-oxygenation and after NE application. However, in 
the 60th min of re-oxygenation, %Amax values were 
higher only for IPC-1 vs. Control. No difference 
was found between IPC-3 %Amax values vs. Control 
(Fig. 1). Moreover, dif-IPC-1 %Amax values were signi-
ficantly higher as compared to dif-IPC-2 analyzed 
together in 10th to 60th min of re-oxygenation 
(10.7 ± 1.82 vs. 7.5 ± 1.37; p < 0.05).
Postconditioning 
Maximal amplitude of systolic peak values 
were significantly higher for POC vs. Control from 
10th to 60th min of re-oxygenation, in the 60th min of 
re-oxygenation and after NE application (Fig. 1). 
There were no significant differences between dif-
-IPC1 and dif-POC (10.7 ± 1.82 vs. 11.58 ± 1.69; 
p < 0.005).
Co-application of preconditioning  
and postconditioning 
Maximal amplitude of systolic peak values 
were significantly lower for IPC-1 + POC vs. 
Control from 10th to 60th min of re-oxygenation 
and in the 60th min of re-oxygenation and after NE 
application.
Sham
Maximal amplitude of systolic peak values 
were significantly higher for Sham vs. Control 
from 10th to 60th min of re-oxygenation and after 
NE application. However the %Amax were gradually 
falling in Sham and were no different from control 
in 60th min of re-oxygenation (Fig. 1).
Discussion
Previous studies utilized animal models to de-
scribe the influence of IPC and POC co-application 
on I/R injury. Our study is the first to assess the 
influence of IPC and POC interaction on hypoxic 
human myocardium in vitro. The main finding of our 
study is that co-application of IPC and POC abolished 
the cardioprotective effect of either intervention 
alone in fragments of human right heart atria.














Age [years] 64.8 ± 3.7 64.7 ± 3.2 58.5 ± 2.7 56.3 ± 2.62 63.5 ± 4.3 59.3 ± 5.2 0.262
Male 7 (70%) 8 (68%) 8 (68%) 9 (75%) 10 (83%) 7 (88%) 0.839
Beta-blockers 8 (80%) 10 (83%) 8 (68%) 9 (75%) 10 (83%) 8 (100%) 0.589
ACEI/ARBII 9 (90%) 9 (75%) 10 (83%) 7 (58%) 10 (83%) 5 (63%) 0.641
CCB 1 (10%) 2 (17%) 1 (8%) 3 (25%) 4 (50%) 4 (33%) 0.237
IPC — preconditioning protocol with single (IPC-1), twice repeated (IPC-2) or three times repeated brief periods of ischemia (IPC-3);  
POC — postconditioning protocol; beta–blockers — beta-adrenergic receptor blockers; ACEI — angiotensin converting enzyme inhibitros; 
ARBII — angiotensin II receptor blockers; CCB — calcium channel blockers
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Our results are in the contrast to previo-
us reports. Animal experiments presented that 
additional POC application did not diminish the 
cardioprotection achieved by IPC alone. IPC and 
POC co-applied in myocardium subjected to 60 
min of lethal ischemia was protective against I/R 
injury and the reduction of the infract size was 
equal to the one achieved by either intervention 
alone [10, 13–15]. Interestingly, the reduction of 
lethal ischemia time to 45 or 30 min resulted in 
a greater infract size reduction for IPC and POC co-
-application, as compared to the either intervention 
alone [13, 15]. Such previously reported outcomes 
of IPC and POC interaction were not depended 
on the used study protocol. The single brief IPC 
ischemia period lasted from 3 to 15 min and was 
repeated up to 3 times, and POC ischemia period 
lasted 10 to 30 s and was repeated from 3 to 6 times 
after lethal ischemia [10, 13–15].
We observed that performed IPC and POC 
protocols in our study successfully protected the 
human myocardium against simulated I/R injury, 
and the level their protection was similar. This 
is in a line with previous findings, where those 
2 endogenous protective mechanisms were equal 
to each other [7, 10, 16, 17]. Moreover, we have 
confirmed that single brief period of ischemia befo-
re lethal ischemia injury is the most effective IPC 
algorithm to protect the human heart in vitro [4]. 
The results of our study shed a light on the 
IPC and POC interaction in human myocardium and 
may help to explain previously observed discrepan-
cies between promising results of ischemic POC 
application in experimental models [5, 17] and its 
less optimistic clinical outcomes. Clinical trials 
reported conflicting results of POC application 
during the percutaneous coronary intervention of 
the infarct related artery. POC triggered cardiopro-
tection [8] or did not protect myocardium against 
I/R injury at all [18]. Such observed discrepancies 
may be related to diverse scenarios of coronary 
artery occlusion. Coronary artery may occlude 
abruptly or may occlude progressively with in-
termittent coronary flow limitations mimicking 
IPC [19, 20]. These 2 different scenarios of the 
myocardial ischemia onset may cause dissimilar 
Figure 1. The myocardial strips function during the re-oxygenation period. Figures present maximal amplitude of 
systolic peak (%Amax) results analysis by two-way ANOVA during within 10th to 60th min of re-oxygenation and by pai-
red t-Student’s test in the 60th min of re-oxygenation and after norepinephrine (NE) application (*p < 0.05 vs. Control) 
for IPC-1 (preconditioning using single hypoxia/re-oxygenation period), IPC-2 (preconditioning using twice repeated 
hypoxia/re-oxygenation period), IPC-3 (preconditioning using three times repeated hypoxia/re-oxygenation period), 
POC (postconditioning using three times repeated hypoxia/re-oxygenation period) and the combined use of IPC-1 and 
POC. Sham refers to non-hypoxic myocardial strips incubation. As Control serves results of hypoxia/re-oxygenation 
injury of myocardial strips.
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outcomes of POC application during the percutaneo-
us coronary intervention of the infarct related artery. 
As it was shown in our study, POC application in the 
myocardium subjected to IPC may abolish overall 
cardioprotection. Thus, POC application in patients 
with the intermittent ischemia symptoms suggesting 
IPC may not be beneficial and POC application may 
only be effective in patients without pre-infarct an-
gina symptoms. Moreover, further investigations are 
needed to determine whether patients’ age influences 
the IPC and POC interaction outcomes. As it was pre-
sented in animal studies, IPC and POC co-application 
was not detrimental to either intervention alone in 
relatively young study population [10, 13–15] what is 
in a contrast to IPC and POC co-application outcomes 
in our aging study group [21].
We may only speculate on the mechanism 
in which the co-application of IPC and POC get 
toxic for the hypoxic human heart. Previous data 
presented that both IPC and POC cardioprotection 
are related to the activity of the nitric oxide syntha-
se and nitric oxide (NO) concentration [22, 23]. 
Although NO at low concentration triggered the 
cardioprotection of human heart [24], its protective 
capacity was lost at high concentration due to the 
increase of free radicals concentration; especially 
the peroxynitrite [25]. It is plausible that, the co-
-application of both IPC and POC increases NO con-
centration to a level that it triggers the excessive 
peroxinitrite production, which is toxic for human 
heart subjected to I/R injury.
Limitations of the study
Firstly, we utilized fragments of human right 
heart atria; not fragments of the left heart ventricle. 
Previous histological studies showed that the atrial 
wall is covered by thicker layer of the endothelium, 
as compared to the heart ventricle’s wall [26]. 
Thicker endothelium is a source of a higher rate 
of NO synthesis in atria, as compared to ventricles 
[27]. An increased NO synthesis was shown to 
protect the myocardium against I/R injury [28], and 
alterations in endothelial NO concentration was 
documented to influence IPC and POC outcomes 
[22, 23]. Such histological differences followed by 
dissimilar NO synthesis rate may cause a diffe-
rent atrial myocardium response to IPC and POC 
stimuli, as compared to ventricular myocardium. 
Secondly, all of the patients received preope-
rative (pre-experimental) pharmacotherapy, what 
is in contrast to the above-mentioned in vitro ani-
mal experiments. However, we excluded patients 
subjected to statin therapy to avoid its detrimental 
effect on IPC and POC protection [29]. 
Thirdly, we observed a relatively rapid decline 
in the systolic function of myocardium not subje-
cted to I/R injury what might indicate an intra-
-experimental myocardial stunning of non-hypoxic 
trabeculae. This calls doubts about the low stability 
of presented bio-assay. But the intention was to 
carry out experiment so long to achieve a decline 
in function in all groups hypoxic and non-hypoxic 
(Sham). This approach gave a chance for a better 
comparison of viability by the use of NE stimuli. We 
found in Sham 3 fold higher viability than in Con-
trol. So we presented high stability of our bioassay 
in terms of myocardial tissue viability.
Finally, we have only assessed the myocardial 
function and did not assess the rate of myocardial 
necrosis and/or apoptosis.
Conclusions
A combined application of IPC and POC proto-
cols abolishes their protective capacity, as compa-
red to the either intervention alone in fragments 
of human right atria. A thorough knowledge about 
IPC and POC interactions in the human heart is 
needed to design the most suitable method of their 
effective application in clinical settings.
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